Phase I/II Study Of Autologous T Cells To Express T-Cell Receptors (TCRs) In Patients With Solid Tumors, Including Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate the safety and efficacy of Neoantigen specific TCR- T cells in patients with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05194735
Study ID: TCR001-201
Trial Phase: Phase I/II
Trial Sponsor: Alaunos Therapeutics
Therapies Used in This Trial: TCR- T cell therapy